medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2023, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2023; 21 (1)

Impact of the covid-19 pandemic on the diagnosis of leprosy in Mexico

Damián-Magaña ÉJ, Sandoval-Navarro KA, Arenas R, Castillo-Solana A

Language: Spanish
References: 19
Page: 13-19
PDF size: 290.97 Kb.


ABSTRACT

Background: in Mexico, in March 2020 the epidemic caused by the SARS-COV-2 virus (COVID-19) was declared a health emergency, which affected the diagnosis and follow-up of diseases such as leprosy. This paper analyzes the epidemiological behavior of leprosy from 2018 to 2022 in Mexico and the impact of the pandemic caused by the SARS-COV-2 virus on its diagnosis.
Material and methods: retrospective and descriptive study of the official data of new cases of leprosy in the Epidemiological Bulletin of México. In addition to the annual incidence of leprosy in the country from 2013 to 2017 in order to calculate the expected incidence and compare it with the actual incidence during the period studied.
Results: a total of 634 cases of leprosy were reported. A decrease in the actual incidence was observed compared to the projected incidence in 2020 and 2022. In all states of the Republic, the lowest number of cases occurred in 2020.
Conclusions: the behavior of leprosy in Mexico had a significant reduction of cases (41.2%) in 2020, coinciding with the date on which COVID-19 health emergency was declared in our country, explaining the impact of this pandemic on leprosy.


REFERENCES

  1. Organización Panamericana de la Salud-Organización Mundial de laSalud, Actualización epidemiológica: nuevo coronavirus (2019-ncov), 5 de febrerode 2020, Washington, ops-oms, 2020.

  2. Secretaría de Salud, Consejo de Salubridad General declara emergenciasanitaria nacional a epidemia por coronavirus covid-19, México,Gobierno de México, marzo de 2020. Disponible en: https://www.gob.mx/salud/prensa/consejo-de-salubridad-general-declara-emergencia-sanitaria-nacional-a-epidemia-por-coronavirus-covid-19-239301#:~:text=El%20d%C3%ADa%20de%20hoy%2-0se,2%20(Covid%2D19).

  3. Informe Técnico Semanal covid-19 México, Subsecretaría de Prevencióny Promoción de la Salud, 03/01/23-17:00 hrs. Disponible en:https://www.gob.mx/cms/uploads/attachment/file/789123/Informe_Tecnico_Semanal_COVID-19_2023.01.03.pdf.

  4. Organización Mundial de la Salud, Enfermedades tropicales desatendidas,16 de enero de 2023. Disponible en: https://www.who.int/es/news-room/questions-and-answers/item/neglected-tropical-diseases.

  5. Global leprosy (Hansen disease) update, 2021: moving towards interruptionof transmission, Weekly Epidemiological Record 2022; 36:429-50.

  6. De Paula HL, De Souza C, Silva SR, Martins-Filho P, Barreto JG, GurgelRQ, Cuevas LE y Santos VS, Risk factors for physical disability inpatients with leprosy: a systematic review and meta-analysis, jamaDermatology 2019; 155(10):1120-8.

  7. Mushtaq S, Leprosy in the post-elimination phase: so near and yet sofar, Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, SocietaItaliana di Dermatologia e Sifilografia 2020; 155(3):269-79.

  8. Da Paz WS, Souza MDR, Tavares DDS, De Jesus AR, Dos Santos AD,Do Carmo RF, De Souza, CDF y Bezerra-Santos M, Impact of the covid-19 pandemic on the diagnosis of leprosy in Brazil: an ecological andpopulation-based study, Lancet Regional Health Americas 2022; 9: 100181.

  9. Han XY, Seo YH, Sizer KC et al., A new mycobacterium species causingdiffuse lepromatous leprosy, Am J Clin Pathol 2008; 130(6):856-64.

  10. Zhang Y, Feng L y Wang L, Leprosy: a life-changing disease, Journal ofthe European Academy of Dermatology and Venereology 2022; 36(9):e695-7.

  11. Romero-Navarrete M, Arenas R, Han XY, Vega-Memije ME y Castillo-Solana AD, Leprosy caused by Mycobacterium lepromatosis, Am J ClinPathol 2022; 158(6):678-86.

  12. Salian VS, Wright JA, Vedell PT et al., covid-19 transmission, currenttreatment, and future therapeutic strategies, Mol Pharm 2021;18(3):754-71.

  13. Clark A, Hill B, Bannerman R, Wohlgemuth L, Burrill J, Agyemang D yGenovezos Ch, Adaptación de un programa integrado de enfermedadestropicales desatendidas en respuesta a covid-19, Transactionsof The Royal Society of Tropical Medicine and Hygiene 2021, 115(5):441-6.

  14. Cáceres-Durán MA, Comportamiento epidemiológico de la lepra envarios países de América Latina, 2011-2020, Rev Panam Salud Pública2022; 46:e14.

  15. Guía de continuidad para garantizar los servicios en las unidades médicasy unidades administrativas de la administración pública federalen la nueva normalidad. Disponible en: https://coronavirus.gob.mx/wp-content/uploads/2020/09/Guia_Continuidad_Servicios_Salud_21Sep2020.pdf.

  16. covid-19: semáforo semanal del 24 de mayo al 6 de junio. Disponibleen: https://coronavirus.gob.mx/semaforo/.

  17. Senado DJ, Los factores de riesgo en el proceso salud-enfermedad,Rev Cubana Med Gen Integr 1999; 15(4):453-60. Disponible en:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21251999000400019&lng=es.

  18. covid-19 data repository by the Center for Systems Science and Engineering(csse) at Johns Hopkins University. Disponible en: https://github.com/CSSEGISandData/COVID-19.

  19. Zodpey SP, Tiwari RR y Salodkar AD, Gender differentials in the socialand family life of leprosy patients, Leprosy Review 2000; 71.




2020     |     www.medigraphic.com